卒中结局与恢复研究的血液生物样本建议
本文为国际卒中遗传学联盟发布的指南,针对卒中恢复的血液生物标志物研究提出建议。作者团队经9个月讨论和两轮匿名调查达成共识,更新并扩展了2015年建议,涵盖采血时机、样本处理与储存、知情同意与数据共享等分析前考虑。
要点
- 卒中恢复研究的血液样本采集需考虑不同于卒中风险研究的独特需求。
- 建议涵盖采血时机、样本处理与储存、知情同意与数据共享等分析前环节。
- 共识基于专家讨论和两轮匿名调查,更新了2015年联盟建议。
核心结论
- 本文提出了适用于卒中恢复血液生物标志物研究的更新建议,以促进大规模数据收集和临床转化。
研究设计与样本
- 指南由国际卒中遗传学联盟提名专家经9个月讨论和两轮匿名调查达成共识制定。
关键数值与推荐
- 推荐涵盖采血时机、样本处理与储存、知情同意与数据共享等分析前考虑。
- 建议适用于阐明恢复生物学、确定遗传变异与结局、识别可成药靶点、预测结局等研究方向。
临床怎么用
- 研究者在设计卒中恢复血液生物标志物研究时应遵循本指南的分析前建议。
- 指南有助于在更大规模上一致地收集人类恢复生物学数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The impact of trait-associated genetic variants on stroke risk is by now a well-established area of research that has continued to accelerate since the introduction of genome-wide technologies. More recently, the field has seen an increasing interest in the biology of stroke recovery. Studies designed to evaluate stroke recovery have unique needs that differ from those in studies of stroke risk and acute stroke outcomes. Here we outline the essential considerations for researchers aiming to develop or contribute to blood biomarker research on stroke recovery. Our recommendations incorporate the latest evidence and technologies that have emerged since the prior International Stroke Genetics Consortium Global Alliance recommendations were published in 2015. Nominated contributors with expertise in stroke recovery and genomics met over the course of 9 months and defined the scope of topics, discussed current practice and standards, and revised the recommendations to reflect consensus achieved through 2 rounds of anonymized surveys. Our writing group defined an updated and expanded set of recommendations applicable to a range of research priorities including (1) elucidating the biology of stroke recovery, (2) determining genetic variations associated with good versus poor stroke outcomes and recovery, (3) identifying druggable (or otherwise therapeutically actionable) gene or protein targets for enhanced recovery, and (4) identifying blood biomarkers that can predict stroke outcomes and recovery. The resulting work offers comprehensive guidance on essential preanalytical considerations for blood biomarker studies, encompassing blood collection timing, specimen processing and storage procedures, and regulatory aspects such as informed consent and data sharing. These guidelines will enable the consistent collection of human data on recovery biology at scale, providing the foundational evidence necessary to drive subsequent clinical translation.
引用
- Braun RG, Edwardson MA, Aldridge CM, et al. Blood Biospecimen Recommendations for Research on Stroke Outcomes and Recovery. Stroke. 2025. PMID: 40982604. doi:10.1161/STROKEAHA.125.050793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。